Pharming Group N.V. (PHAR)
NASDAQ
Key stats Fiscal year 2025
Income statement
- Revenue
- 376,134,000 26.6%
- Net income
- 2,851,000
- Gross profit
- 330,634,000
- Operating income
- 25,842,000
- Earnings per share
- 0.00
- R&D expense
- 100,367,000
Growth and profitability
- Gross margin
- 87.90
- Operating margin
- 6.87
- Net margin
- 0.76
- Return on equity
- 1.03
- Return on assets
- 0.57
- Free cash flow margin
- 14.35
Balance sheet
- Total assets
- 499,963,000
- Shareholders' equity
- 277,102,000
- Cash and equivalents
- 145,305,000
- Current ratio
- 2.59
Cash flow and ratios
- Operating cash flow
- 54,708,000
- Free cash flow
- 53,959,000
- Interest coverage
- 131.85
Shareholder returns
- Shares outstanding
- 701,680,440
- Book value per share
- 0.39
Company information
- Headquarters
- Leiden, P7
- Exchange
- NASDAQ
- Fiscal year end
- 12-31
- Industry (SEC)
- Pharmaceutical Preparations
Fiscal year end: · Source: SEC EDGAR
Pharming Group N.V. trades on NASDAQ under the ticker symbol PHAR. This page brings together its price chart, company profile, key financial figures and technical indicators.